There is now growing evidence that early complement proteins of the classic pathway C1q and C4 are protective and their absence predisposes to SLE, whereas the activation of terminal components of complement, C5b-C9, is pro-inflammatory and deleterious in SLE patients. The gene discussed is C5; the disease is systemic lupus erythematosus.